As other organs, the heart is composed of highly differentiated, very specialized parenchymal cells (cardiomyocytes) surrounded by stroma consisting of extracellular matrix (ECM), tissue fluid and undifferentiated, pluripotent mesenchymal cells. The maintenance of matrix integrity involves the synthesis and degradation of its major components, including collagens, glycoproteins, glycosaminoglycans and proteoglycans.
The ECM-degrading proteinases can be subdivided into three main classes: serine proteinases, metalloproteinases and cysteine proteinases. Matrix metalloproteinases (MMPs) make up a family of more than 20 zinc-containing endoproteinases that can be subdivided into four groups based on their substrate specificity and primary structure [1] . The first group, the collagenases, include MMP-1 (interstitial collagenase), MMP-8 (neutrophil collagenase) and MMP-13 (collagenase 3), which can all cleave fibrillar collagens (types I, II and III). Group 2, the gelatinases (MMP-2 and MMP-9), is well known for its ability to degrade gelatins and type IV collagen in basement membranes. Group 3 constitutes the stromelysins (MMP-3, MMP-10 and MMP-11), so named because they are active against a broad spectrum of ECM components, including proteoglycans, laminins, fibronectin, vitronectin and some types of collagens. Group 4 contains the membrane-type MMPs (MT-MMPs), which degrade several ECM components and are also able to activate other MMPs.
The expression of MMPs is regulated at the transcriptional level by a variety of inflammatory cytokines, hormones and growth factors [1] . In addition, a cell-surface protein that induces MMP expression, termed extracellular matrix metalloproteinase inducer (EMMPRIN) has been identified recently in a number of tissue types, including human myocardium [2] . The MMPs, first synthesized as inactive zymogen precursors, must be activated by proteolytic cleavage. Fully activated MMPs can be inhibited by interaction with naturally occurring, specific inhibitors, the tissue inhibitors of metalloproteinases (TIMPs; 1-4) [3] . Thus, the actual activity of MMPs depends on the rate of synthesis, activation, and the balance between active enzyme and inhibitors.
Form the pioneer work by Montfort and Perez-Tamayo [4] it is well known that MMPs are present in the normal myocardium. Myocardial MMPs are produced by fibroblastlike cells and inflammatory cells, as well cardiomyocytes [5, 6] , and they are predominantly present in their latent form [7] . Emerging evidence is giving rapid momentum to the concept that dysregulation of myocardial MMPs and secondary alterations in ECM degradation modulate major features of myocardial pathology and, thus, mediate crucial steps in the development of heart failure [8] . This recognition provides new insight into the pathogenesis of cardiac diseases and further provides new potential targets for intervening [9] . Myocardial fibrosis may illustrate well the above concept.
Myocardial fibrosis is the end result of altered ECM turnover, where synthesis of matrix proteins, namely fibrillar type I and III collagens, exceeds their degradation [10] . It is becoming clear that fibrosis is not a unique pathological process but is due to excess in the same biological events involved in normal tissue repair. A central event in tissue repair is the release of cytokines in response to injury. Several lines of evidence point to transforming growth factor-β (TGF-β) as a key cytokine that initiates and terminates tissue repair and whose sustained production underlies the development of tissue fibrosis [11] .
Although all three isoforms of TGF-β (TGF-β 1 , -β 2 and -β 3 ) are present in the heart, the level of the type 1 isoform seems to be particularly related to the development of myocardial fibrosis. Transgenic mice overexpressing TGF-β 1 exhibit fibrosis of the heart and other organs [12] . In contrast, age-associated myocardial fibrosis is diminished in heterozygous TGF-β 1 -deficient mice [13] . The fibrogenic potential of TGF-β 1 is uniquely powerful because of its simultaneous ability to stimulate matrix synthesis and to inhibit matrix degradation. In fact, it has been shown that TGF-β 1 stimulates production of collagen molecules and other ECM proteins by isolated cardiac fibroblasts [14, 15] . In addition, TGF-β 1 has been shown to inhibit interstitial collagenase and to stimulate TIMPs in cultured cardiac fibroblasts [16, 17] .
In this issue of the Journal, Seeland et al. [18] have investigated the balance between MMPs and TIMPs in the heart of TGF-β 1 -overexpressing transgenic mice. Whereas expression and activity of interstitial collagenase was depressed in transgenic mice compared with nontransgenic controls, TIMPs 1, 2 and 4 were abnormally overexpressed in the myocardium of transgenic mice. Although Seeland et al. do not supply functional evidence of the involvement of these specific components of the MMPs/TIMPs system in myocardial fibrosis, these initial observations certainly raise the hypothesis that a diminished collagenase activity may participate in the development of fibrosis in fibrogenic cardiac conditions characterized by an excess of TGF-β 1 .
Various evidence points to hypertensive heart disease as one of these cardiac conditions. In fact, increased TGF-β 1 expression and increased accumulation of collagen fibres have been reported in the hypertrophied left ventricle of adult spontaneously hypertensive rats [19, 20] . Furthermore, it has been shown that both interstitial collagenase activity and collagen degradation are reduced in the left ventricle of these animals [21, 22] . Finally, recent data show that an association exists between increased levels of TGF-β 1 and diminished collagen type I degradation in patients with essential hypertension and left ventricular hypertrophy [23] .
Progressive myocardial fibrosis is both a major cause of heart failure and an important contributor to the cost of health care [24] . An exaggerated accumulation of collagen fibres initially raises myocardial stiffness and compromises ventricular filling; its continuous accumulation further increases stiffness and decreases diastolic function, and may also impair ventricular contractility [10] . Thus, it has been proposed that regression of the myocardial fibrosis present in chronic cardiac diseases represents a goal of pharmacological interventions aimed to prevent heart failure [25] . In this conceptual framework, the findings reported by Seeland et al. [18] would suggest that suppression of the TGF-β 1 -inhibition of collagenase may be useful in regressing myocardial fibrosis in fibrogenic cardiac diseases.
Some recent experimental and clinical observations add support to this possibility in the context of hypertensive heart disease. Brilla et al. [21] found that angiotensinconverting enzyme inhibition with lisinopril resulted in an increase in myocardial interstitial collagenase activity and reversal of myocardial fibrosis in spontaneously hypertensive rats with left ventricular hypertrophy. On the other hand, Varo et al. [22] demonstrated that chronic angiotensin II type 1 receptor blockade with losartan was associated with increased myocardial interstitial collagenase activity, diminished myocardial TIMP-1 expression, increased collagen type I degradation and reversal of fibrosis in the hypertrophied left ventricle of spontaneously hypertensive rats. The potential clinical relevance of these data is given by recent findings showing that chronic treatment with either lisinopril [26] or losartan [27] resulted in biopsy-proven regression of myocardial fibrosis and improvement of parameters assessing diastolic function in patients with essential hypertension and left ventricular hypertrophy. Interestingly, the ability of these two compounds to reduce myocardial collagen deposition was independent of their antihypertensive efficacy. Furthermore, increased collagen type I degradation, increased interstitial collagenase levels and diminished TGF-β 1 levels have been reported in hypertensives treated with these antihypertensive agents [23, 28] .
Collectively the above findings would suggest that the pharmacological interference with angiotensin II may lead to suppression of TGF-β 1 -mediated inhibition of interstitial collagenase which, in turn, may result in increased fibrillar collagen degradation and regression of the myocardial fibrosis present in hypertensive heart disease. This possibility is in agreement with a number of in vivo and in vitro observations indicating that angiotensin II regulates cardiac fibroblast function and myocardial collagen deposition via TGF-β 1 [29] .
The finding by Seeland et al. [18] that gelatinase (MMP-2 and MMP-9) expression was unaltered in the myocardium of TGF-β 1 transgenic mice deserves some comment.
A number of studies have demonstrated increased expression and activity of MMPs other than collagenases, namely gelatinases, in the myocardium of animals [5, 30] and patients [2, 31] presenting with ventricular dilatation and heart failure after myocardial infarction. Furthermore, myocardial levels of interstitial collagenase have been found to be diminished in these patients [2] . In addition, it has been shown that acute pharmacological inhibition of MMPs [32] or deficiency in MMP-9 [33] attenuates left ventricular dilatation in the infarcted mouse heart. Together, these studies suggest a causal relationship between exaggerated proteolytic activity, disruption of the myocardial ECM, architectural remodelling of the heart, and deterioration of cardiac performance. Furthermore, they provide the basis for the proposal that specific MMP inhibitors could be used as a potential therapy for patients at risk for the development of heart failure after myocardial infarction [34] .
One question arises regarding which factors are responsible for the specific patterns of MMP expression and activity in different cardiac diaseases, i.e. hypertensive heart disease or ischaemic heart disease. One possibility is that myocardial MMPs are under genetic control. In this regard, in the promoters of MMPs, including interstitial collagenase and MMP-9, polymorphisms have been identified, which appear to influence MMP gene expression [35] . For instance, polymorphisms in MMP-9 have already been associated with the severity of ischaemic heart disease [36] . Thus, variations in the levels of MMP transcription in patients suffering from hypertensive heart disease or ischaemic cardiomyopathy might contribute to differences in ECM degradation, pathological changes of the left ventricle, and compromise of cardiac function. Further research is needed to identify a possible correlation between these events and MMP polymorphisms. The observations that levels of MMPs and TIMPs are differentially altered in the serum of patients with hypertensive heart disease [28] or after myocardial infarction [37] have raised the possibility that MMP and TIMP levels could predict the clinical outcome.
